Bicara Therapeutics Inc
Veridion Score
Composite trend over time
Why is BCAX moving today?
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Real vendor fields plus Veridion-computed history. Missing fields stay blank.
Warehouse intelligence for BCAX.
BCAX insider activity
Bicara Therapeutics Inc
4 insiders bought in the last 90 days
Net buying: $32.5M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | 2026-05-21 | Hyep Ivan | Insider | sell | $20.42 | 9,200 | 145,355 | $188K | SEC Form 4 |
| 2026-05-26 | 2026-05-21 | Hyep Ivan | Insider | buy | $3.79 | 9,200 | 154,555 | $35K | SEC Form 4 |
| 2026-05-18 | 2026-05-15 | Cohlhepp Ryan | Insider | sell | $20.29 | 4,500 | 191,641 | $91K | SEC Form 4 |
| 2026-05-18 | 2026-05-15 | Cohlhepp Ryan | Insider | sell | $20.29 | 8,000 | 196,141 | $162K | SEC Form 4 |
| 2026-05-18 | 2026-05-15 | Cohlhepp Ryan | Insider | buy | $3.79 | 8,000 | 204,141 | $30K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 108 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moBCAX contract awards, year to date.
Public federal awards linked to this ticker.
BCAX lobbying filings, year to date.
Registered lobbying filings matched to Bicara Therapeutics Inc.